Organigram Global (OGI) to Release Quarterly Earnings on Monday

Key Points

• Organigram Global will report Q2 2026 results before the market opens on May 11, 2026 at 8:00 AM ET; analysts expect ($0.01) EPS and $50.71 million in revenue.
• In the prior quarter OGI missed estimates, reporting ($0.02) EPS vs. ($0.01) expected and revenue of $46.27 million, with a net margin of 6.03% and a negative return on equity of 15.41%.
• The stock trades around $1.42 with a market cap near $199 million, institutional investors own about 34.6% of the shares, and Wall Street's consensus rating is "Hold".

Organigram Global (NASDAQ:OGI - Get Free Report) is projected to issue its Q2 2026 results before the market opens on Monday, May 11th. Analysts expect Organigram Global to post earnings of ($0.01) per share and revenue of $50.7080 million for the quarter. Investors are encouraged to explore the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 8:00 AM ET.

Organigram Global (NASDAQ:OGI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.01). The business had revenue of $46.27 million during the quarter, compared to analyst estimates of $73.38 million. Organigram Global had a net margin of 6.03% and a negative return on equity of 15.41%. On average, analysts expect Organigram Global to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Global Stock Performance

NASDAQ OGI traded down $0.01 during trading on Monday, reaching $1.42. The company's stock had a trading volume of 62,837 shares, compared to its average volume of 726,699. The firm has a market cap of $199.19 million, a price-to-earnings ratio of 10.18 and a beta of 1.50. Organigram Global has a twelve month low of $1.09 and a twelve month high of $2.24. The business's fifty day moving average price is $1.41 and its 200-day moving average price is $1.56.

Institutional Investors Weigh In On Organigram Global

Hedge funds and other institutional investors have recently modified their holdings of the stock. Walleye Capital LLC bought a new stake in shares of Organigram Global in the 4th quarter worth about $25,000. StoneX Group Inc. acquired a new position in shares of Organigram Global in the 4th quarter valued at about $30,000. HRT Financial LP acquired a new position in shares of Organigram Global in the 4th quarter valued at about $52,000. Bank of America Corp DE boosted its holdings in shares of Organigram Global by 1,678.1% in the 3rd quarter. Bank of America Corp DE now owns 37,357 shares of the company's stock valued at $76,000 after buying an additional 35,256 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Organigram Global in the 4th quarter valued at about $188,000. Institutional investors own 34.63% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. ATB Cormark Capital Markets downgraded shares of Organigram Global from a "strong-buy" rating to a "moderate buy" rating in a research note on Wednesday, February 11th. Canaccord Genuity Group began coverage on shares of Organigram Global in a research note on Tuesday, January 27th. They set a "buy" rating on the stock. Finally, Wall Street Zen raised shares of Organigram Global from a "sell" rating to a "hold" rating in a research note on Saturday, February 14th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Organigram Global presently has a consensus rating of "Hold".

Organigram Global Company Profile

Organigram Global Inc NASDAQ: OGI is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company's product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.